Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia

Objective: To describe the clinical characteristics of pediatric patients aged6 to 17 years diagnosed with moderate to severe allergic asthma undergoingtreatment with omalizumab (OMB) from January 2007 to February 2014 in6 cities in Colombia. Methods: This retrospective, longitudinal cohort studyinc...

Descripción completa

Detalles Bibliográficos
Autores Principales: Morales Munera,Olga Lucía, Pedraza,Angela María, Niño Serna,Laura Fernanda
Formato: Objeto de conferencia (Conference Object)
Lenguaje:Inglés (English)
Publicado: Jhon Wiley & Sons 2016
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/26486
https://doi.org/10.1002/ppul.23409
id ir-10336-26486
recordtype dspace
spelling ir-10336-264862020-08-06T16:24:08Z Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia Curso clínico de asma de niños tratados con Omalizumab: estudio multicéntrico Colombia Morales Munera,Olga Lucía Pedraza,Angela María Niño Serna,Laura Fernanda Medical and Health Sciences Paediatrics and Reproductive Medicine Objective: To describe the clinical characteristics of pediatric patients aged6 to 17 years diagnosed with moderate to severe allergic asthma undergoingtreatment with omalizumab (OMB) from January 2007 to February 2014 in6 cities in Colombia. Methods: This retrospective, longitudinal cohort studyincluded 63 children and adolescents. Evaluated outcomes includedsymptoms control, exacerbations frequency, decreased use of asthmacontrol drugs and presence of adverse events before starting treatment andafter 4 and 12 months of OMB use. Results: after 4 and 12 months oftreatment 89% and 96.6% of children under 12 years of age (p ¼ 0.0015) and78% and 91.6% of children over 12 years of age (p ¼ 0.0145) had goodsymptom control, respectively. Furthermore, after 12 months, the number ofexacerbations decreased to 2 (p ¼ 0.00), the frequency of beta2 rescueinhaler use decreased to 0.37 days (p ¼ 0.00), and the use of controller drugsdecreased in 73% of patients, including decreased use of inhaledcorticosteroids in 62%. Only one severe adverse event was reported inone patient. Conclusion: OMB is an effective drug for the clinical control ofmoderate and severe allergic asthma. It reduces asthma symptoms andexacerbations and exhibits good tolerance and few severe adverse event 2016-04 2020-08-06T16:24:08Z info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/publishedVersion ISSN: 8755-6863 EISSN: 1099-0496 https://repository.urosario.edu.co/handle/10336/26486 https://doi.org/10.1002/ppul.23409 eng info:eu-repo/semantics/openAccess application/pdf Jhon Wiley & Sons Pediatric Pulmonology
institution EdocUR - Universidad del Rosario
collection DSpace
language Inglés (English)
topic Medical and Health Sciences
Paediatrics and Reproductive Medicine
spellingShingle Medical and Health Sciences
Paediatrics and Reproductive Medicine
Morales Munera,Olga Lucía
Pedraza,Angela María
Niño Serna,Laura Fernanda
Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
description Objective: To describe the clinical characteristics of pediatric patients aged6 to 17 years diagnosed with moderate to severe allergic asthma undergoingtreatment with omalizumab (OMB) from January 2007 to February 2014 in6 cities in Colombia. Methods: This retrospective, longitudinal cohort studyincluded 63 children and adolescents. Evaluated outcomes includedsymptoms control, exacerbations frequency, decreased use of asthmacontrol drugs and presence of adverse events before starting treatment andafter 4 and 12 months of OMB use. Results: after 4 and 12 months oftreatment 89% and 96.6% of children under 12 years of age (p ¼ 0.0015) and78% and 91.6% of children over 12 years of age (p ¼ 0.0145) had goodsymptom control, respectively. Furthermore, after 12 months, the number ofexacerbations decreased to 2 (p ¼ 0.00), the frequency of beta2 rescueinhaler use decreased to 0.37 days (p ¼ 0.00), and the use of controller drugsdecreased in 73% of patients, including decreased use of inhaledcorticosteroids in 62%. Only one severe adverse event was reported inone patient. Conclusion: OMB is an effective drug for the clinical control ofmoderate and severe allergic asthma. It reduces asthma symptoms andexacerbations and exhibits good tolerance and few severe adverse event
format Objeto de conferencia (Conference Object)
author Morales Munera,Olga Lucía
Pedraza,Angela María
Niño Serna,Laura Fernanda
author_facet Morales Munera,Olga Lucía
Pedraza,Angela María
Niño Serna,Laura Fernanda
author_sort Morales Munera,Olga Lucía
title Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
title_short Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
title_full Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
title_fullStr Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
title_full_unstemmed Clinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
title_sort clinical course of asthma of children treatedwith omalizumab: multicenter study colombia
publisher Jhon Wiley & Sons
publishDate 2016
url https://repository.urosario.edu.co/handle/10336/26486
https://doi.org/10.1002/ppul.23409
_version_ 1675439925989736448
score 11,828437